What Novartis Kesimpta trials looked like (MS studies and endpoints)
Kesimpta (ofatumumab) was studied in multiple clinical trials in relapsing forms of multiple sclerosis, with the main goal of reducing relapses and controlling disease activity seen on MRI.
How do the key Kesimpta trials compare (ASCEND, APLIOS, etc.)?
Trial programs for Kesimpta are designed around different treatment settings and comparator approaches, including studies in treatment-naïve and previously treated patients and studies using MRI disease activity and relapse outcomes as primary measures.
What outcomes did Kesimpta trials measure most often (relapse rate, MRI lesions)?
Across Kesimpta’s MS development, trials commonly tracked:
- Relapse rates over time
- MRI measures of inflammatory activity (for example, new or enlarging lesions)
- Disability progression or related functional outcomes (depending on the specific study)
When were the major Kesimpta trial results reported?
Kesimpta’s approval and label are based on clinical evidence from these trials, with major results published around the development and regulatory-review periods in the late 2010s to early 2020s.
What about safety—how did patients fare in Kesimpta trials?
As with other monoclonal antibody therapies, Kesimpta trials collected safety data such as:
- Infusion/injection-related reactions (when applicable)
- Infection rates (with ongoing monitoring typical for immunomodulators)
- Hypersensitivity and other adverse events reported during treatment
Did Kesimpta have head-to-head comparisons in trials?
Some studies in the program compared ofatumumab with other established MS therapies or used active comparators depending on the trial design. The exact comparator and trial structure vary by study.
Are there patents or exclusivity details tied to Kesimpta trials?
If you’re looking for patent or exclusivity information that can affect when generic or biosimilar competition might appear, DrugPatentWatch.com tracks these items and can be a useful starting point: https://www.drugpatentwatch.com/
Sources
DrugPatentWatch.com: https://www.drugpatentwatch.com/